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Objective: To assess the cost-effectiveness of 3 treatments (tiotropium, salmeterol, and no 
treatment) in patients with moderate chronic obstructive pulmonary disease (COPD).
Methods: A Markov model with a time horizon of 1 year was developed. A hypothetical 
cohort of 100,000 subjects with moderate COPD with mean age of 65 years, smoking history 
of 50 pack-years, and disease duration of 9.5 years were included in the model. The efficacy 
and withdrawal data were taken from published randomized clinical trials. The effectiveness 
measure was exacerbations avoided per patient per year. Incremental cost-effectiveness ratio 
(ICER) was calculated as additional cost per patient to prevent 1 exacerbation, compared with 
the next most expensive option. A payer’s perspective was used and only direct costs were 
included in the study. Sensitivity analyses were conducted to test the robustness of the baseline 
estimates and study assumptions.
Results: The mean annual costs for the no treatment, salmeterol, and tiotropium groups were 
$392.1, $1268.7, and $1408.6, respectively. The ICER of tiotropium compared with no treat-
ment was $1817.36 per exacerbation avoided, while the ICER of salmeterol compared with 
no treatment was $2454.48 per exacerbation avoided. Thus, in patients with moderate COPD, 
tiotropium is more cost-effective than salmeterol and no treatment.
Keywords: cost-effectiveness, chronic obstructive pulmonary disease, markov model, 
tiotropium, salmeterol
Introduction
Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized 
by chronic cough, sputum production, and dyspnea which leads to restricted activity, 
disability, and poor quality of life (QoL).1–3 The disease is highly prevalent and is 
increasing worldwide.4 It has been estimated that 10 to 16 million people in the 
United States (US) have been diagnosed with some form of COPD and as nearly 14 to 
16 million still remain undiagnosed.5,6 COPD is the fourth leading cause of death after 
heart disease, cancer, and cerebrovascular disease and is projected to be the third lead-
ing cause of death by the year 2020.3,6,7 It is one of the leading causes of morbidity and 
mortality worldwide and also imparts a substantial economic burden on individuals as 
well as on society.3 The total cost of COPD in the US is projected to be $49.9 billion in 
2010, of which $29.9 billion is attributed to direct cost (cost associated with medical 
and pharmacy resource utilization).1
COPD is a respiratory disease characterized by airflow limitation that is not 
fully reversible. The airflow limitation is progressive and associated with an 
abnormal inflammatory response of the lungs. COPD mainly comprises chronic ClinicoEconomics and Outcomes Research 2010:2 26
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bronchitis and emphysema. In chronic bronchitis, there is 
inflammation and swelling of the airway linings that lead 
to narrowing and obstruction of the airways. This inflam-
mation triggers the production of mucous (sputum), which 
causes further obstruction of the airways. Emphysema is a 
condition in which the walls between the alveoli or air sacs 
within the lung lose their ability to stretch and recoil. The 
air sacs become weakened and break and the elasticity of 
the lung tissue is lost. Air trapping in the air sacs impairs 
the exchange of oxygen and carbon dioxide. In 2002, the 
National Health Interview Survey reported that in patients 
above 65 years of age, 5.4% were diagnosed with chronic 
bronchitis and 4.8% with emphysema.3,7
COPD is classified into 4 stages based on the level of 
disease severity:3
Stage 0: At risk: This stage is characterized by chronic 
cough and sputum production. Lung function, as measured 
by spirometry, is normal.
Stage I: Mild COPD: This stage is characterized by mild 
airflow limitation (forced expiratory volume in 1 second 
[FEV1] versus forced vital capacity [FVC] 70% but 
FEV1  80% predicted) with or without cough and sputum 
production. At this stage, the individual may not even be 
aware that his or her lung function is abnormal.
Stage II: Moderate COPD: This stage is characterized by 
worsening airflow limitation (50%  FEV1  80% predicted) 
and progression of symptoms, with shortness of breath. At this 
stage the patients typically seek medical attention because of 
dyspnea or disease exacerbation. There is a significant impact 
on patient QoL.
Stage III: Severe COPD: This stage is characterized by 
severe airflow limitation (30%  FEV1  50% predicted) or 
the presence of respiratory failure or clinical signs of right 
heart failure.
Stage IV: Very severe COPD: At this stage, the FEV1 
 30% predicted. The individual’s QoL is appreciably 
impaired and exacerbations may be life-threatening. In 
addition to the FEV1, body mass index (BMI) and dyspnea 
have proved useful in predicting outcomes such as survival 
in severe COPD.
Effective management at early stages of disease is thus 
crucial. Management of mild to moderate COPD involves 
avoidance of risk factors to prevent disease progression and 
use of pharmacotherapy options to control symptoms.8,9 
Early identification and management can prove beneficial by 
avoiding a major portion of healthcare costs associated with 
emergency visits and hospitalizations, thereby reducing the 
healthcare costs considerably.
COPD is undoubtedly a very costly disease if left 
untreated. With the introduction of new treatment strategies 
in treating COPD, there is a necessity to identify the most 
cost-effective strategies. An effective selection from the avail-
able treatment strategies by decision-makers can be beneficial 
both clinically as well as an economically. However, given 
the dearth of information on the economic consequences of 
different treatment strategies used for COPD, there is a need 
to conduct economic analyses to optimize treatment selection 
and guide better decision-making.
Global Initiative for Chronic Obstructive Pulmonary Dis-
ease (GOLD) and American Thoracic Society (ATS) guide-
lines recommend use of bronchodilators (anticholinergics 
and β2-agonists) as first-line therapy in treating patients with 
moderate COPD.3,6 The guidelines, however do not mention 
any specific preference between the two drug classes under 
bronchodilators: β2-agonists and anticholinergics, to be used 
as first-line therapy. The long-acting bronchodilators such as 
β2-agonists that are available by prescription in the US include 
salmeterol (Serevent®; GlaxoSmithKline), and formoterol 
(Foradil®; Schering-Plough), and the long-acting anticho-
linergics include tiotropium (Spiriva®; Pfizer/Boehringer 
Ingelheim).
Salmeterol and formoterol are administered twice daily, 
while tiotropium is administered just once daily. Data from 
randomized clinical trials have shown the clinical superior-
ity of tiotropium, a long-acting anticholinergic, over other 
bronchodilators.10 However, the cost of tiotropium is much 
higher in comparison to salmeterol, a long-acting β2-agonist. 
The unit cost price of tiotropium is $130.63, while that of sal-
meterol is $113.47.11 Thus, it remains to be seen if tiotropium 
(Spiriva®) is cost-effective as first-line therapy in comparison 
to salmeterol (Serevent®) when used over an extensive period 
of time. In addition, the once-a-day dosing may prove to be 
more convenient and provide more consistent bronchodilation 
than twice daily administration of salmeterol (Serevent®).3,6 
This dosing of tiotropium may also increase the likelihood 
of patient compliance.12–14 It is well established that non-
compliance with medication therapy results in therapeutic 
failure and dramatic increase in healthcare use.12–14 Thus, 
tiotropium has benefits over salmeterol for clinical efficacy 
as well as dosing convenience but is an expensive treatment 
compared to salmeterol.
There are few studies in the literature that have esti-
mated the cost-effectiveness of tiotropium and salmeterol. 
However, no economic study comparing tiotropium and 
salmeterol has been done from a US payer perspective. These 
two medications have an advantage over other medications ClinicoEconomics and Outcomes Research 2010:2 27
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used in COPD in that they are long-acting and require less 
frequent administration than other drugs.15–19 This study 
aims at developing a decision analytical model to measure 
the cost-effectiveness of 3 treatment strategies: tiotropium, 
salmeterol, and no treatment. A Markov model, a type of 
decision analytic model, was developed to compare the costs 
and effects of tiotropium, salmeterol, and no treatment. A 
Markov model with a 6-month time cycle and an analytical 
time frame of 1 year was developed. The goal was to sum-
marize costs and outcomes of tiotropium, salmeterol, and 
no treatment and to identify the most cost-effective option 
in patients with moderate COPD.
Study objectives
The overall aim of the study was to determine if tiotropium 
(long-acting anticholinergic), is more cost-effective than 
salmeterol (long-acting beta agonist) and no treatment. The 
no treatment comparison group included data derived from 
patients on the placebo arm of clinical trials of these drugs.
The specific objectives were:
Objective 1: To develop a Markov model to assess the 
cost-effectiveness of tiotropium, salmeterol, and no treatment 
in patients with moderate COPD.
Objective 2: To develop cost-effectiveness models based 
on the Markov model to determine the incremental costs and 
consequences of tiotropium, salmeterol, and no treatment in 
patients with moderate COPD.
Methodology
A literature search was conducted to identify all clinical 
trials conducted to date for tiotropium and salmeterol (see 
Table 1). A Markov model was constructed using the deci-
sion analytical model technique Figure 1.20 The Markov 
model was developed using Data TreeAge Pro software.21 
The model evaluated the cost-effectiveness of 3 treatments: 
tiotropium, salmeterol, and no treatment in patients with 
moderate COPD. Data for tiotropium and salmeterol were 
derived from the respective clinical trials while the no 
treatment group included data derived from the patients on 
placebo in these clinical trials. The placebo was plain lactose 
capsules, administered via a dry powder inhaler device. The 
patients in the control/placebo/no treatment group were 
permitted albuterol metered-dose inhaler, inhaled steroids 
and oral steroids (up to the equivalent of prednisolone, 10 
mg/day) during the baseline period and throughout the entire 
study, as needed to relieve symptoms. The main analytical 
plan was to calculate incremental cost- effectiveness ratios 
(ICERs).
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On Treatment
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[+]
Figure 1 Markov model demonstrating the various Markov states.
Notes: (+) indicates that the same tree is repeated for each of the arms.
The decision model comprised of two mutually exclusive 
Markov states: ‘on treatment’, and ‘maintenance therapy’. 
The on treatment branch represents patients who continue on 
the treatment which they were started on (either tiotropium, 
salmeterol or no treatment). The maintenance therapy branch 
represents alternate treatment option for those patients who 
do not continue on treatment. The patients on each treatment 
arm may either be on treatment or on maintenance therapy. 
The patients on treatment have a chance of experiencing one 
of the two events: 1) they may either respond to the treatment 
or 2) they may show an inadequate response to treatment. An 
inadequate response includes patients who withdraw from 
treatment due to lack of medication effect, or side-effects or 
death. Since there is a chance of experiencing either of the 
two events, it is represented by a chance node. The patients 
with an inadequate response continue on maintenance 
therapy. The maintenance therapy state for this study was 
assumed to comprise the following: short-acting anticho-
linergic (ipratropium), short-acting β-agonist (albuterol), 
theophylline, and an inhaled steroid (fluticasone).15 These 
medications were selected on the basis of clinical opinion 
and GOLD guidelines.3 The doses and dosage frequency of 
these medications are:
Ipratropium: 2 puffs (40 µg), 4 times a day.
Albuterol: 2 puffs (90 µg), 4 times a day.
Theophylline: 400 µg once a day.
Steroid (fluticasone nasal spray): 50 µg twice daily.
The patients who respond to the treatment may either 
experience an exacerbation or no exacerbation. Those who 
do not experience exacerbation will continue using the same 
treatment. However, patients who experience exacerbation 
may have a severe or a nonsevere exacerbation. Nonsevere 
exacerbations are the ones that can be controlled by contin-
ued use of on treatment medication. Patients with nonsevere 
exacerbation will continue on the same treatment strategy. 
However, patients experiencing severe exacerbation will 
then be prescribed an additional steroid medication3 along 
with the initial treatment which the patient was on. Thus, 
an additional steroid medication (fluticasone) cost will be 
incurred by this group. Patients with severe exacerbation 
could either be hospitalized or may undergo outpatient treat-
ment. Those who undergo hospitalization even after continu-
ing the same treatment will then be switched to maintenance 
therapy, while those who undergo outpatient treatment will 
continue using the same treatment. Hospitalization costs 
will be incurred by patients who undergo hospitalizations ClinicoEconomics and Outcomes Research 2010:2 29
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and outpatient costs will be incurred by the patients who 
respond to treatment.
Model characteristics
Patient population
The patient population in the model was a hypothetical cohort 
of 100,000 male patients with a mean age of 65 years, a smok-
ing history of at least 50 pack-years, and disease duration 
of at least 9.5 years. The characteristics of the hypothetical 
patients were selected to closely reflect the characteristics of 
the patient population included in the randomized clinical 
trials of the treatments.15,18,19,22
Cycle length
The cycle length selected for this study was 6 months, 
because at the time the study was conducted (2006) no 
long-term study had been done, and the duration of most 
randomized clinical trials at that time of the treatments in 
COPD was 6 months.
Perspective
The study was conducted from a third-party payer 
perspective. Thus, only direct costs of COPD were considered 
in the analysis. Direct costs included in the study were drug 
costs, hospitalization costs, monitoring costs, and physician 
visit costs.
Analytical time frame
Since most third-party payers are interested in cost over a 
period of 1 to 3 years, the ICERs of the treatments were 
modeled over a period of 1 year.
Outcome measure
The outcome measure considered in this study was cost 
per exacerbation avoided per patient per year. ICERs were 
calculated as additional cost per patient to prevent 1 exacer-
bation, compared with the next most expensive option. The 
uncertainty of the baseline estimates and study assumptions 
was tested by conducting sensitivity analyses. If the ranges 
for variables from literature were not available, a ±20% 
range of the base-case estimate was used in the sensitivity 
analyses.
Analysis
This model was evaluated using the Monte Carlo simulation 
technique. Monte Carlo simulation is a computer simula-
tion technique, which involves estimating the approximate 
probability of outcomes by running multiple simulations, 
using various random variables as inputs Monte Carlo has an 
advantage over cohort simulation technique in that it provides 
a better measure of variability associated with the parameters 
than with estimates in a cohort simulation.23,24 Sensitivity 
analysis was done for the following variables: probability 
of exacerbation, probability of hospitalization, probability 
of severe exacerbation, and compliance.
Operationalizing the model
The efficacy rates for tiotropium, salmeterol, and no treat-
ment group were obtained from published clinical trials. 
The efficacy data for the no treatment group are the data 
obtained for placebo arms of clinical trials for tiotropium 
and salmeterol.15,18,19,22 For tiotropium, 3 studies were 
identified. In a study by Casaburi and colleagues,18 the 
exacerbation rate per patient per year for tiotropium was 
0.086. Around 36% patients on tiotropium had at least 
1 exacerbation per year. In a study by Vincken and col-
leagues,15 patients on tiotropium had 0.073 exacerbations 
per patient per year. Around 35% patients on tiotropium had 
at least one exacerbation per year. In a study by Donohue 
and colleagues,22 the exacerbations per patient per year was 
not reported. Around 36.8% patients on tiotropium had at 
least 1 exacerbation per year.
For salmeterol, 2 studies were identified whose data were 
used in our study. In a study by Donohue and colleagues,22 
38.5% patients on salmeterol had at least 1 exacerbation 
per year. The exacerbation rate per patient per year was not 
reported. In a study by Rennard and colleagues,19 20.7% 
patients on salmeterol showed at least 1 exacerbation per 
year. For the no treatment group (placebo), 3 studies were 
identified. In a study by Casaburi and colleagues,18 the rate 
of exacerbation per patient per year was found to be 0.161. 
Around 42% patients on no treatment (placebo) had at least 1 
exacerbation per year. In a study by Donohue and colleagues, 
45.8% patients on no treatment (placebo) had at least 1 exac-
erbation per patient per year. In a study by Rennard,19 32.9% 
patients on no treatment (placebo) had at least 1 exacerbation 
per patient per year.
Data
Probabilities
The transition of patients during each cycle from one Markov 
state to another state is called transition probability. These 
transition probabilities were derived from published random-
ized clinical trials of various treatments. The transition from 
one event to another was also taken from published literature ClinicoEconomics and Outcomes Research 2010:2 30
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(see Table 2). The probability was calculated from rates 
derived from clinical trials using the following formula:
    P = [1- e (-r) (t) ]
where, P = probability, r = rate, t = time
Costs
Since the study assumes a third-party payer perspective, only 
direct costs were taken into consideration. The direct costs 
included drug costs, hospitalization costs, monitoring costs, 
and physician visits costs. The drug costs which include cost 
of tiotropium and salmeterol were taken from the Red book.11 
Also, cost of maintenance therapy which includes an anti-
cholinergic (ipratropium), β-agonist (albuterol), theophylline, 
and steroid (fluticasone) were taken from Red book.11
The laboratory test and monitoring tests included spi-
rometry, chest X-ray, complete blood count, hepatic function 
profile, electrocardiogram monitoring and analysis, and 
sputum gram stain. These tests were identified with Current 
Procedural Terminology (CPT) codes and the costs were 
derived from Medical Insurance Reimbursement-based 
Maximum Allowable Charges (MACs) for the year 2006.25 
Physician visit costs as well as hospitalization costs were also 
derived from the same source. All costs included in the study 
were for the year 2006 (see Table 3). Since no old costs or 
future costs were included in the analysis, there was no need 
to inflate or discount costs in this study.
Model assumptions and rationale
Compliance is a very important aspect in determining effec-
tiveness of a medication treatment. According to a study 
by Cramer and colleagues, compliance rate was highest for 
tiotropium compared to other bronchodilator drugs (94% to 
76%).26 In the present study, we assumed the compliance rate 
Table 2 Probability values (6-month data taken from clinical trials; ranges for sensitivity analysis)
No treatment Salmeterol Tiotropium
Sensitivity analysis Sensitivity analysis Sensitivity analysis
   Base-case  
value
Low  
value
High  
value
Base-case 
value
Low  
value
High  
value
Base-case 
value
Low  
value
High  
value
Probability of exacerbation 0.2897 0.1895 0.39 0.35 0.343 0.357 0.2424 0.1648 0.32
Probability of hospitalization 0.04795 0.0459 0.05 0.05 0.049 0.051 0.0274 0.0247 0.03
Probability of severe 
exacerbation
0.145  0.1  0.2  0.15215  0.138  0.167  0.285  0.112  0.4579 
Table 3 Cost dataa (6-month data; ranges for sensitivity analysis)
   Unit cost ($)  Cost for 6 months ($ range   
for sensitivity analysis)
Laboratory tests
Arterial blood gas 48.34 48.34 (48.32–49.30)
spirometry 59.89 59.89 (58.69–61.08)
Chest X-ray 50.96 50.96 (49.94–51.97)
ECg monitoring 253.21 253.21 (248.14–258.27)
sputum gram stain 24.06 24.06 (23.57–24.54)
Hospitalization/day 366.49
Physician visit 94.26 94.26 (92.37–96.14)
Drug costs
Tiotropium (18 µg once daily) 130.63 783.78 (768.10–799.45)
salmeterol (50 µg twice daily) 113.40 680.80 (667.18–694.41)
ipratropium (2 puffs of 40 µg 4 times a day) 84.60 609.12 (596.98–621.30)
Albuterol (2 puffs of 90 µg 4 times a day) 29.79 214.48 (209.65–218.82)
Theophylline (400 mg once daily) 85.75 154.35 (151.26–157.43)
Fluticasone (50 µg twice daily) 50.00 348.00 (341.04–354.96)
aAll costs reported in 2006 Us$.ClinicoEconomics and Outcomes Research 2010:2 31
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for patients on tiotropium to be 90%. In a study by Holt and 
colleagues, it was found that the compliance rate in patients 
with a combination of salmeterol and fluticasone inhaler was 
almost 75%.27 Since there are no studies in the literature on 
compliance rate with salmeterol alone; the study assumed a 
compliance rate with salmeterol as 75%. Also, according to the 
literature, the overall level of compliance with use of inhaled 
medications in the treatment of asthma was on average found 
to be 50%.28 In this study it that the level of compliance for the 
no treatment group was assumed to be 50%. This assumption 
was necessary to quantify the cost and consequences of intro-
ducing agents under real world practice. However, base-case 
estimates of compliance were varied in the sensitivity analysis 
to test their impact on the study results.
The study assumed that the hypothetical patients will not 
suffer from any other co-morbid conditions and hence will 
not consume any other medications. This assumption was 
necessary since it is not feasible to quantify the usage of dif-
ferent medications in the presence of co-morbid conditions. 
The study also did not take into consideration patients on 
nebulizers since the study population comprised of patients 
with moderate COPD only. Typically, patients on nebulizers 
are usually those who are at a more severe stage of disease 
or are physically limited in their ability to use devices. The 
study was done only for a period of 1 year and it is assumed 
that during this 1-year period, the disease condition of the 
patient remains the same and that the patients did not transi-
tion into a higher level of disease severity.
Results
Base-case analysis
A total of 100,000 hypothetical patients aged 65 years, with 
smoking history of 50 pack years, and disease duration of 
9.5 years were sampled for the three treatments using a 
first-order Monte Carlo simulation. Estimated mean costs 
and effectiveness are reported in Table 4. The mean annual 
cost of treatment in no treatment group was the lowest 
($392.1), followed by salmeterol ($1,268.66) and highest for 
tiotropium ($1,408.59). The mean effectiveness was highest 
for tiotropium (1.129 exacerbations avoided per patient per 
year) followed by salmeterol (1.052 exacerbations avoided 
per patient per year) and no treatment group (0.694 exacerba-
tions avoided per patient per year). The results for direct costs 
are also represented graphically in Figure 2, where the x-axis 
represents effectiveness (exacerbations avoided per patient 
per year) and the y-axis gives the direct cost in dollars.
An incremental analysis was conducted to identify the 
most cost-effective treatment (see Table 5). The ICER of 
tiotropium compared with no treatment group (reference 
group) was $1,817.37 per exacerbation avoided, while the 
ICER of salmeterol compared with no treatment group 
was $2,454.48 per exacerbation avoided. The strategy of 
salmeterol is dominated by a blend of no treatment and 
tiotropium with a coefficient of inequity between 0.138 
and 0.177 (0.138  k  0.177). The principal of ‘extended 
dominance’ was used in our incremental cost-effectiveness 
study to eliminate the strategy (salmeterol) whose costs and 
effectiveness are improved by a mixed strategy of (tiotropium 
and no treatment) (Figure 2). Coefficient of inequity is gener-
ally applied to demonstrate that only a small proportion of the 
Table 4 Base-case analysis for direct cost and effectiveness using Monte Carlo simulations of 100,000 hypothetical patients with mod-
erate COPD
Direct cost ($) Effectiveness (exacerbation avoided/patient/year)
Strategy Mean (SD) Minimum Median Maximum Mean (SD) Minimum Median Maximum
No treatment 392.1 (134.74) 304.405 384.405 972.995 0.69443 (0.4376) 0.18875 0.56625 1.85025
salmeterol 1268.66 (309.83) 644.815 1325.64 1919.02 1.05156 (0.51591) 0.28313 0.84938 2.13338
Tiotropium 1408.59 (311.79) 696.295 1480.08 2073.46 1.12855 (0.46041) 0.33975 1.01925 2.30325
Abbreviation: sD, standard deviation.
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population would receive an inferior health care strategy if a 
mixed strategy were used instead of the dominated strategy.29 
These results indicate that tiotropium is the most cost-effec-
tive of the three treatments for patients with moderate COPD. 
Thus, the ICER for tiotropium indicates that to produce one 
unit of outcome (exacerbation avoided per patient per year) 
in patients on tiotropium, an additional $1,817.37 cost is 
incurred compared to the reference group, while to produce 
the same outcome in patients on salmeterol, an additional cost 
incurred is $2,454.48 compared to the reference group.
sensitivity analysis
The base-case estimates were varied over a range (if available 
from the literature) to study the impact on the final results. In 
the absence of a range, a ±20% value of base-case estimates 
was considered in the analysis. The following variables were 
subjected to one-way sensitivity analysis: probability of 
exacerbation, probability of severe exacerbation, probability 
of hospitalization, and compliance with medications.
The study results were sensitive to changes in compli-
ance rates of treatments. Several cases were seen where 
tiotropium was dominated by salmeterol when compli-
ance rates were altered. With 100% compliance in each of 
the treatment strategies, the direct costs for no treatment, 
salmeterol and tiotropium were observed to be $302.2, 
$1,267.9 and $1,407.2, respectively and effectiveness to 
be 0.883, 1.146, and 1.165, respectively. The ICER was 
found to be $3,327.03 for salmeterol and $7,554.64 for 
tiotropium group.
Compliance values were then varied (±20%) for the dif-
ferent groups. With tiotropium 75%, salmeterol 75%, no 
treatment 50% compliance, the ICERs were $2,451.06 and 
$7,361.94 for salmeterol and tiotropium, respectively. With 
tiotropium 90%, salmeterol 50%, no treatment 50% compli-
ance, the ICERs were $3,338 and $8,213.82, respectively. 
With tiotropium 90%, salmeterol 100%, no treatment 50% 
compliance, the ICERs were $1,932.55 for salmeterol and 
tiotropium was dominated. With tiotropium 90%, salmeterol 
75%, no treatment 25% compliance, the ICERs were $1,940.1 
and $1,828.86, respectively. With tiotropium 90%, salmeterol 
75%, no treatment 75% compliance, the ICERs were $3,324.99 
and $1,847.11, respectively. We observe that as the compliance 
was changed, the ICERs changed drastically (see Figure 3).
Discussion
The results from the decision modeling analysis indicate 
that tiotropium is the most cost-effective treatment. From 
the base-case analysis, the mean costs for the no treatment 
group were the lowest ($392.6), followed by salmeterol 
($1,268.7) and tiotropium ($1,408.6). The mean effective-
ness in terms of exacerbations avoided per patient per year 
for tiotropium, salmeterol, and no treatment were found to 
be 1.129, 1.052 and 0.694, respectively. Tiotropium provides 
more health benefits and is more costly than salmeterol and 
no treatment. The ICER of tiotropium compared with no 
treatment was $1,817.37 per exacerbation avoided, while the 
ICER of salmeterol compared with no treatment group was 
$2,454.48 per exacerbation avoided per patient per year. Thus, 
results demonstrate tiotropium to be more cost-effective than 
salmeterol and no treatment.
The study was conducted from a payer’s perspective 
since the amount of information in the literature enables 
only the direct costs involved to be measured. The study was 
conducted over a 1-year period and would help the payer 
identify the cost that can be offset by incorporating the most 
cost-effective treatment strategy. However, given the enor-
mous economic impact of COPD on the society, it would be 
interesting to see the cost-effectiveness of new treatments 
from a societal perspective.
The literature search identified 6 cost-effectiveness stud-
ies for tiotropium and salmeterol.30–35 The results of this study, 
however, cannot be directly compared to these economic stud-
ies, since the methodology, strategies used, and type of study 
are not exactly the same. All studies indicated that tiotropium 
Table 5 Base-case analysis of direct costs, effectiveness, and incremental cost-effectiveness ratios (iCER) of different treatments using 
Monte Carlo simulation of 100,000 hypothetical patients with moderate COPD
Treatment 
 
Direct costs ($) 
 
Effectiveness  
(exacerbations  
avoided/patient/year)
Cost/effectiveness  
($/exacerbations  
avoided/patient/year)
ICER ($/exacerbations 
avoided/patient/year) 
No treatment  392.1 0.694 564.636
salmeterol 1268.7 1.052 1206.46 2454.48
Tiotropium 1408.6 1.129 1248.14 1817.37
Notes: Extended dominance report:  The strategy ‘salmeterol’ is dominated by a blend of ‘no treatment’ group and ‘tiotropium’ with a coefficient of inequity between 0.138 
and 0.1777.ClinicoEconomics and Outcomes Research 2010:2 33
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was more cost-effective and also equivalent clinically in 
terms of effectiveness, which included exacerbations avoided, 
reduction in hospital admissions, and reduction in overall 
health care costs.30–35
The mean annual cost derived in this study for tiotro-
pium was $1,408.6. Also, tiotropium showed an effective-
ness of 1.129 exacerbations avoided per patient per year. 
The difference in the effectiveness of tiotropium and 
salmeterol was found to be 0.077. In a study by Oostenbrink 
and colleagues,34 the mean difference in the number of 
exacerbations was 0.17 in favor of tiotropium compared to 
salmeterol. The costs could not be compared directly since 
the studies measured costs in euros and this study measured 
costs in dollars. The results from the study by Maniadakis 
and colleagues30 conducted in Greece demonstrated a mean 
annual cost per patient of €2,504 in the tiotropium arm and 
€2,655 in the salmeterol arm, indicating tiotropium to be 
more cost-effective than salmeterol. Also, the study by Lee,35 
conducted in Singapore indicated a high level of decrease in 
overall cost per year per patient being treated with tiotropium 
bromide. Our study findings were in accordance with findings 
from the studies conducted in Greece and Singapore.
The results from sensitivity analysis showed that 
there is no significant change in the costs associated with 
the three treatments and tiotropium was shown to dominate 
both salmeterol and no treatment. However, the results 
were sensitive to changes in exacerbation probabilities and 
also when different compliance rates were included in the 
study. The analysis was run by varying probability values 
and compliance rates of all three treatments within a range 
of ±20%. With a –20% change in probability of exacerbation 
for tiotropium, tiotropium was dominated by salmeterol. In 
all other cases, tiotropium dominated salmeterol.
The sensitivity analysis for compliance rates shows that 
the direct cost associated with no treatment is $392.2, sal-
meterol $1,267.3 and tiotropium $1,407.5. Also, the results 
indicate that varying compliance values has a significant 
effect on the ICERs. Thus, compliance is a very important 
parameter which needs to be addressed and taken into 
consideration. It would be interesting to see how the cost-
effectiveness ratios change once more standard and defini-
tive compliance data from clinical studies of each of these 
treatments become available.
This study has several strengths. The model effectively 
incorporates the various pathways patients with moderate 
COPD could undergo. The progression of the tree is in accor-
dance to information obtained from published literature and 
inputs from expert opinion. This enabled us to create a stable 
economic model to evaluate the cost-effectiveness of different 
bronchodilator treatments in moderate COPD. This model is 
valid clinically and is based on GOLD treatment guideline stan-
dards for moderate COPD. The patient population identified in 
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this study is clearly defined and only patients with moderate 
COPD were considered. Although, robust data were available 
for most key variables, a few variables did not have high-quality 
estimates. For instance, there is a limited amount of informa-
tion available in the literature on compliance of patients with 
tiotropium and salmeterol. In order to tackle this limitation, a 
series of scenarios using sensitivity analysis was run.
This study has several limitations. The main limitation 
relates to the availability of data. An ideal data source would 
be a randomized clinical trial with a large sample size of 
COPD patients with similar disease severity, comparing 
all three COPD treatments (tiotropium, salmeterol, and no 
treatment). In the absence of such a study, data have to be 
collected from different sources, each having their advantages 
and limitations. Also, the efficacy data are derived from only 
4 published clinical trials. Despite the base-case population 
in the model being well matched with the clinical trial popu-
lation; there are generalizability issues with the base-case 
estimates. Extensive sensitivity analyses were conducted to 
address this limitation.
There is a dearth of information on the compliance of 
patients with moderate COPD using bronchodilator medica-
tions. This is another major limitation of the study. In this 
study, different scenarios using sensitivity analysis were 
tested to see the effect of this important variable on the ICER 
of different treatments. The different results obtained indicate 
that compliance is a very important factor which has a strong 
effect on cost-effectiveness of any treatment strategy. A future 
study could be designed to capture the compliance rate of 
COPD patients on tiotropium, salmeterol, and no treatment, 
and to measure how compliance affects the overall outcomes 
as well as healthcare costs.
There is an increased need for well designed pharmaco-
economic models as new, specially designed, more effective 
drugs, biologics and high-cost medications are introduced 
into the market. In such a scenario, there is a need to identify 
those medications with the greatest effect on medication 
costs. This study provides valuable information for payers, 
policy-makers, and other decision-makers in the formulary 
review process and for rational clinical decision-making for 
patients with moderate COPD, until evidence can be accumu-
lated from claims and postmarketing clinical studies.36
In current clinical practice, however, different combination 
treatment strategies are most commonly followed. Combina-
tion therapy allows for lower doses and thereby improves 
safety. Several recent studies have shown better clinical out-
comes in the treatment of COPD patients when combination 
strategies are used. TOwards a Revolution in COPD Health 
(TORCH) was a randomized double blind trial, comparing 
combination therapy with inhaled steroids (ICS – fluticasone) 
and long-acting β2-agonists (LABA – salmeterol) with 
placebo (short-acting bronchodilators on demand), LABA 
alone or ICS alone for a duration of 3 years.37 The primary 
outcome was all-cause mortality, and the frequency of exacer-
bations, QoL and rate of decline in FEV1 were also assessed. 
The combination therapy significantly reduced the annual 
exacerbation rates from 1.13 to 0.85, and also improved the 
health status as well as lung function. Understanding Potential 
Long-term Impacts on Function with Tiotropium (UPLIFT), 
a randomized, double-blind trial, compared tiotropium with 
placebo for 4 years.38 Patients were allowed to use all available 
relevant medications. The primary outcome was the rate of 
decline in mean FEV1, and secondary outcomes, the frequency 
of exacerbations, QoL, and mortality, were also assessed. 
Tiotropium reduced the risk of COPD exacerbations by 14% 
(95% confidence interval) and the risk of respiratory failure 
by 33%; all-cause mortality during the treatment period was 
reduced by 16%. Tiotropium also showed improvement in lung 
function and health status over 4 years, reduced exacerbations, 
reduced cases of respiratory failure and improved survival.
A study by Calverley et al39 showed that combination 
therapy with salmeterol and fluticasone improved lung 
function, symptoms, and health status and reduced use of 
rescue medication and frequency of exacerbations. Simi-
larly, another study by Mahler et al40 examined the benefits 
of combining fluticasone propionate with salmeterol to 
treat the inflammatory and bronchoconstrictive components 
of COPD. The results of combination treatment strategy 
improved airflow obstruction, and provided clinical benefits 
such as reduced severity of dyspnea, reduced use of rescue 
albuterol, and improved health status.
The Canadian Optimal trial41 aimed at identifying whether 
combining tiotropium with salmeterol or with fluticasone–sal-
meterol improves the clinical outcomes in moderate to severe 
COPD compared with tiotropium alone. It was a randomized, 
double-blind, placebo-controlled trial conducted in 27 aca-
demic and community medical centers in Canada over a period 
of 3 years. The combination treatment strategy with tiotropium 
plus fluticasone–salmeterol reduced hospitalization rate as 
well as improved health-related QoL and lung function.
Based on the same study, Najafzadeh et al42 conducted a 
cost-effectiveness analysis comparing effect on cost on adding 
salmeterol or fluticasone–salmeterol to tiotropium for COPD. 
The results indicated an improvement in health outcomes but 
with an increase in associated costs. Tiotropium, fluticasone–
salmeterol and tiotropium–salmeterol combination therapies ClinicoEconomics and Outcomes Research 2010:2 35
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were not found to be economically attractive alternatives to 
monotherapy with tiotropium.
Conclusions
COPD is one of the leading causes of morbidity and mor-
tality worldwide and imparts substantial economic burden 
on society. New treatments are introduced with the goal of 
optimizing health state of patients. Clinical studies of treat-
ment options suggest that both tiotropium and salmeterol are 
effective for patients with moderate COPD. The GOLD and 
ATS guidelines list both treatment options as appropriate 
for controlling disease. An economic analysis is therefore 
an appropriate next step to help with decision-making.
However, there is insufficient quantitative economic 
information available to guide decision-making and treat-
ment selection to minimize the cost effects of this disease. 
This study evaluated the potential cost-effectiveness of two 
alternative treatment interventions in patients with moder-
ate COPD. The results will assist private and public payers 
in evaluating medication choices for effective therapy. The 
study results demonstrate that use of tiotropium in patients 
with moderate COPD is more cost effective than salmeterol 
and no treatment. In context, tiotropium, despite a higher 
average wholesale price, may be justified as first choice for 
controlling moderate COPD.
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